WilmerHale Advises Apellis Pharmaceuticals in $117 Million Public Offering
- 3.11.2019
On March 11, 2019, Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, announced the closing of its underwritten public offering of 6,900,000 shares of its common stock at a public offering price of $17.00 per share, which includes 900,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares at the public offering price, less underwriting discounts and commissions. Gross proceeds from the offering totaled $117.3 million, before deducting underwriting discounts and commissions and expenses payable by Apellis.
Stuart Falber led the WilmerHale team representing Apellis, with a team that included Craig Hilts, Byron Crowe, Bruce Manheim, Julie Hogan Rodgers, Ben Kelsey and Heidi Treiber.
